PH12013500432A1 - Anti-vegfr-3 antibody compositions - Google Patents

Anti-vegfr-3 antibody compositions

Info

Publication number
PH12013500432A1
PH12013500432A1 PH1/2013/500432A PH12013500432A PH12013500432A1 PH 12013500432 A1 PH12013500432 A1 PH 12013500432A1 PH 12013500432 A PH12013500432 A PH 12013500432A PH 12013500432 A1 PH12013500432 A1 PH 12013500432A1
Authority
PH
Philippines
Prior art keywords
vegfr
antibody compositions
antibodies
disease
treatment
Prior art date
Application number
PH1/2013/500432A
Other languages
English (en)
Inventor
Krishnadatt Persaud
Bronislaw Pytowski
Nathalie Zayek
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500432(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PH12013500432A1 publication Critical patent/PH12013500432A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH1/2013/500432A 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions PH12013500432A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07
PCT/US2011/050131 WO2012033696A1 (en) 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions

Publications (1)

Publication Number Publication Date
PH12013500432A1 true PH12013500432A1 (en) 2017-08-23

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500432A PH12013500432A1 (en) 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions

Country Status (26)

Country Link
US (2) US8481034B2 (https=)
EP (1) EP2614081B1 (https=)
JP (1) JP2013538813A (https=)
KR (1) KR20130042601A (https=)
CN (1) CN103080133A (https=)
AR (1) AR082641A1 (https=)
AU (1) AU2011299443B2 (https=)
BR (1) BR112013005423A2 (https=)
CA (1) CA2809375C (https=)
CL (1) CL2013000607A1 (https=)
CO (1) CO6690754A2 (https=)
CR (1) CR20130065A (https=)
DO (1) DOP2013000039A (https=)
EA (1) EA023331B1 (https=)
EC (1) ECSP13012481A (https=)
ES (1) ES2568801T3 (https=)
GT (1) GT201300058A (https=)
MA (1) MA34487B1 (https=)
MX (1) MX2013002718A (https=)
PE (1) PE20131328A1 (https=)
PH (1) PH12013500432A1 (https=)
SG (1) SG188265A1 (https=)
TW (1) TWI413527B (https=)
UA (1) UA109148C2 (https=)
WO (1) WO2012033696A1 (https=)
ZA (1) ZA201300804B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
EP3244924B1 (en) * 2015-01-15 2021-04-07 Oncoquest Pharmaceuticals Inc. Methods of increasing delivery of anti-cancer agents to targets
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353952B1 (en) * 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
BRPI0616923A2 (pt) 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica

Also Published As

Publication number Publication date
WO2012033696A1 (en) 2012-03-15
CA2809375C (en) 2016-02-09
US20130280278A1 (en) 2013-10-24
US8784818B2 (en) 2014-07-22
ECSP13012481A (es) 2015-03-31
ZA201300804B (en) 2014-07-30
CO6690754A2 (es) 2013-06-17
CL2013000607A1 (es) 2014-04-11
DOP2013000039A (es) 2013-04-15
TWI413527B (zh) 2013-11-01
SG188265A1 (en) 2013-04-30
BR112013005423A2 (pt) 2016-06-07
JP2013538813A (ja) 2013-10-17
EA023331B1 (ru) 2016-05-31
PE20131328A1 (es) 2013-11-18
MX2013002718A (es) 2013-05-01
EP2614081B1 (en) 2016-03-16
KR20130042601A (ko) 2013-04-26
US20120058126A1 (en) 2012-03-08
ES2568801T3 (es) 2016-05-04
EA201390117A1 (ru) 2013-06-28
TW201223543A (en) 2012-06-16
AR082641A1 (es) 2012-12-19
AU2011299443A1 (en) 2013-02-14
US8481034B2 (en) 2013-07-09
UA109148C2 (uk) 2015-07-27
MA34487B1 (fr) 2013-08-01
AU2011299443B2 (en) 2014-06-05
CA2809375A1 (en) 2012-03-15
CN103080133A (zh) 2013-05-01
CR20130065A (es) 2013-03-21
GT201300058A (es) 2014-07-16
EP2614081A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
NZ707086A (en) Anti-cd40 antibodies and methods of use
TN2015000396A1 (en) Antibody drug conjugates
MA34091B1 (fr) Anticorps anti-cd40
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX347020B (es) Anticuerpo contra el csf-1r.
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MX2013009151A (es) Inmunoterapia mejorada.
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
AU2016219704A1 (en) Anti-Notch1 antibodies
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
EA201390467A1 (ru) Композиции антител и способы применения
TN2015000277A1 (en) Bmp-6 antibodies
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions